A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, Burke JN, Harrington CC, Lively KJ, Lyons HF, Munshi NC, Anderson KC, Trippa L, Richardson PG, Raje NS.
O'Donnell EK, et al. Among authors: raje ns.
Br J Haematol. 2018 Jul;182(2):222-230. doi: 10.1111/bjh.15261. Epub 2018 May 8.
Br J Haematol. 2018.
PMID: 29740809
Free PMC article.
Clinical Trial.